Metabolic Disease and Urea Cycle Disorder Research
Immedica Pharma AB is involved in clinical research focused on arginase 1 deficiency (ARG1-D), a rare inherited metabolic disorder affecting the body’s ability to process arginine and manage the urea cycle.
- Arginase 1 deficiency (ARG1-D)
- Rare genetic metabolic disease
- Arginine metabolism
The sponsor’s research activity is centered on pediatric patients, including children under two years of age, with attention to early-life disease management in a rare enzymatic deficiency.
Pediatric Rare Disease Therapeutics
The clinical research portfolio includes treatment-focused work in infant and early childhood populations with inborn errors of metabolism, reflecting interest in conditions that present in the first years of life.
- Pediatric patients
- Infant rare disease care
- Early-onset metabolic conditions
Current activity involves a study of pegzilarginase in very young children, indicating a therapeutic focus on rare pediatric disease management.
Enzyme Replacement and Targeted Biologic Therapy
Immedica Pharma AB’s funded research highlights interest in enzyme-based treatment strategies for disorders driven by impaired metabolic conversion, with emphasis on restoring biochemical balance in ARG1-D.
- Pegzilarginase
- Biologic therapy
- Metabolic pathway correction
The therapeutic domain is closely tied to arginine-lowering approaches in a rare disease setting, supporting research into precision treatment for a specific enzymatic target.
